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Purpose. We report a case of a 60-year-old male who underwent sequential Onyx embolizations of a cerebral arteriovenous
malformation (AVM) which we implicate as the most likely etiology of subsequent acute respiratory distress syndrome (ARDS).
Methods. Case report and literature review. Results. Shortly after the second Onyx embolization procedure, the patient declined
from respiratory failure secondary to pulmonary edema. Clinical entities typically responsible for pulmonary edema including
cardiac failure, renal failure, iatrogenic volume overload, negative-pressure pulmonary edema, and infectious etiologies were
evaluated and excluded. The patient required mechanical ventilatory support for several days, delaying operative resection. The
patient met clinical and radiographic criteria for ARDS. After excluding other etiologies of ARDS, we postulate that ARDS
developed as a result of Onyx administration. The Onyx copolymer is dissolved in dimethyl sulfoxide (DMSO), a solvent excreted
through the lungs and has been implicated in transient pulmonary side eﬀects. Additionally, a direct toxic eﬀect of the Onyx
copolymer is postulated. Conclusion. Onyx embolization and DMSO toxicity are implicated as the etiology of ARDS given the lack
of other inciting factors and the close temporal relationship. A strong physiologic rationale provides further support. Clinicians
should consider this uncommon but important complication.
1.Historyand Presentation
This 60-year-old male initially presented with a history
of seizures and progressive left-sided hemiparesis. A 3cm
AVM was discovered in the right posterior frontal lobe,
just anterior to the central sulcus (Figure 1). The patient’s
pastmedical history included hypertension, diet-controlled
diabetes mellitus, and mild chronic obstructive pulmonary
disease. Medications included levetiracetam for seizure con-
trol and metoprolol for hypertension. Given the progressive
symptomatology, it was decided to perform an operative
resection of the AVM after sequential Onyx embolization
procedures.
2.InterventionsandHospital Course
On admission day one, the patient underwent the ﬁrst of
two preoperative embolization procedures. Both procedures
were performed under general anesthesia with endotracheal
intubation. Arteriography demonstrated feeding of the AVM
via both middle cerebral artery (MCA) and anterior cerebral
artery (ACA) branches, with early venous drainage via a
large cortical vein near the entry into the superior sagittal
sinus. AnanteriorfeedingbranchoﬀtheMCAwasselectively
catheterized using an UltraFlow microcatheter and Mirage
microwire (Ev3 Neurovascular, Irvine, Calif, USA). When
a position adjacent to the nidus was achieved, the Onyx
was injected per the standard procedure. The dead space
volume of the microcatheter was displaced with 0.26mL
DMSO. Onyx- 18 embolization of the prefrontal branch was
performed using 0.8mL at an injection rate of 0.1mL/min
until there was reﬂux into the feeding vessel. A second
feeding vessel was then selectively catheterized, and due to
the apparent higher ﬂow rate, Onyx-34 was used. 1.6mL
of the Onyx was injected after the same DMSO ﬂush. The
Onyx appeared to ﬁll the nidus well with no noted venous2 Critical Care Research and Practice
Figure 1: AP and lateral projections of angiogram of right
selective internal carotid artery injection showingthe arteriovenous
malformationinthislatearterialphase,withﬁllingofalargevenous
channel into the superior sagittal sinus.
ﬁlling. Follow-up angiography demonstrated improvement
in the transit time into the draining vein but some residual
AVM. The patient was hemodynamically stable through
the procedure and had no respiratory diﬃculties. He was
extubated uneventfully and transferred to the neurosciences
intensive care unit for monitoring and strict blood pressure
control.
The immediate postembolization course was compli-
cated by a brief self-limited seizure requiring only supportive
care. The postprocedure CT scan revealed a small amount
of subarachnoid hemorrhage in the right sylvian ﬁssure
adjacent to the AVM, embolization material within the
AVM, and a small tail of Onyx extending through the
draining vein into the superior sagittal sinus (Figure 2). The
patient’s neurological exam was otherwise unchanged. On
postembolization day one, the patient had a mildly increased
creatinine to 1.25mg/dL, despite a positive ﬂuid balance
of 1.2 liters, which was attributed to the induced relative
hypotension below the patient’s baseline compounding a
contrast nephropathy. He required increasing levels of sup-
plemental oxygen via nasal cannula despite postprocedure
spirometry and pulmonary toilet.
The following day, the patient was assumed to be
clinically stable and so underwent a second embolization
procedure.The anteriorcerebralartery (ACA)wasselectively
catheterized, and using the same microcatheter as above,
two separate feeding vessels to the AVM were identiﬁed
and injected with Onyx for a total volume of 1.6mL of
Onyx-34 and 0.52mL of DMSO to occupy the catheter dead
space. Subsequent angiography demonstrated no further
supply to the AVM nidus from the ACA but persistent
ﬁlling via small, distal MCA branches. Venous drainage to
the sagittal sinus and vein of Labbe remained patent. This
second embolization procedure was well tolerated by the
patient without any oxygenation diﬃculties throughout the
case and an uneventful postprocedure extubation. Over the
next 24 hours, however, the patient’s respiratory function
declined with an increased work of breathing ultimately
mandating intubation and mechanical ventilatory support.
A CT angiogram of the chest was then performed to evaluate
for pulmonary emboli and elucidate other etiologies of
respiratory failure. The CT imaging demonstrated perihilar
and bibasilar ground glass opacities and bibasilar interlobar
septal thickening with Kerley B-lines, all consistent with
pulmonary edema (Figure 3). There were no vascular ﬁlling
defects, excludingthe diagnosis ofvisible pulmonary emboli.
This pulmonary edema was conﬁrmed as noncardiogenic
in origin as echocardiography performed the same day
demonstrated hyperdynamic ventricular function (ejection
fraction of 70%) and wall motion, without valvular abnor-
malities or diastolic dysfunction. The patient was clinically
euvolemic with a normal urine output and a stable serum
creatinine after the second embolization procedure. The
patient’s gas exchange was poor with a PaO2:FiO2 ratio
of 64–71 on hospital days 3 and 4. Imaging and diagnostic
criteria were consistent with a diagnosis of ARDS. The
p a t i e n td i dn o td e m o n s t r a t ea n yo ft h et y p i c a lr i s kf a c t o r s
associated with ARDS, including pneumonia, aspiration,
reperfusion pulmonary edema, sepsis, pancreatitis, drug
overdose, or transfusion of blood products, leaving the
most likely etiology being administration of Onyx during
embolization procedures. The patient remained afebrile, and
there was no evidence of infection throughout his course.
Supportive pulmonary and systemic care followed,
including lung protective ventilatory strategies and mini-
mization of infused crystalloid. Six days later, the patient’s
respiratory function had improved and the patient under-
went a successful frontoparietal craniotomy and AVM
resection. The patient was extubated shortly after and was
discharged home in good condition after a sixteen-day
hospitalization.
3.Discussion
Since endovascular embolization of cerebral AVMs was ﬁrst
described in 1960, numerous agents have been used to
occlude the nidus or feeding arteries, all with various pros
and cons [1]. In 1990, Taki and colleagues reported the
development and successful use of ethylene vinyl alcohol
copolymer (EVAC) for AVM embolization [2]. The formu-
lation of this copolymer, mixed in a dimethyl sulfoxide
(DMSO) solvent and combined with micronized tantalum
(a radio-opacifying agent), is now marketed as Onyx (EV3
Neurovascular, Irvine, Calif, USA) and is FDA approved for
endovascular embolization of cerebral AVMs. Several case
series of its use and clinical eﬃcacy in this setting have since
been reported [3–5]. Other observational series reporting
eﬃcacyusingOnyxforendovasculartreatmentofaneurysms
and dural arteriovenous ﬁstulae are increasingly common
[6–8]. While all of these reports evaluated cerebral outcomes
andrelatedcomplications,noneaddressedpotentialsystemic
complications related to Onyx.
Systemic pulmonary complications related to cerebral
Onyx embolization have been reported elsewhere andCritical Care Research and Practice 3
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Figure 2: Bone windows of CT of the head after ﬁrst embolization, showing high attenuation embolic material (Onyx) in the nidus of the
AVM (a) as well as extension through the draining vein and a thin strand in the superior sagittal sinus.
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Figure 3: AP chest X-ray and accompanying select axial CT slice from the day of respiratory deterioration. The typical “ground glass”
appearance and consolidationis noted.
attributed to the toxicity of the copolymer’s solvent, DMSO
[9]. DMSO [(CH3)2SO] is soluble in aqueous and organic
media making it an eﬃcient solvent for water insoluble
compounds. Thus, it has been used as a biochemical solvent
and a vehicle for drug therapy. It is this property that
facilitatesdissipation ofthe DMSOin thebloodstream while
the Onyx copolymer forms a spongy occlusive cast in the
injected artery. Its other properties as a cell-diﬀerentiating
agent and a hydroxyl radical scavenger led to its various
therapeutic applications for rheumatologic disorders, anti-
cancer therapies, and dermatologic disorders [9]. It is
perhaps these properties that also lead to less desirable side
eﬀects and its potential toxicity to blood vessels both at
the site of injection and at other end organs. DMSO has
been shown to evoke an inﬂammatory response, vasospasm,
and endothelial necrosis following intra-arterial injection.
It is important to note however that several investigations
demonstrated these eﬀects at higher volumes and infusion4 Critical Care Research and Practice
rates than typically used during cerebral Onyx embolization
[10, 11]. Another etiology of potential pulmonary toxicity
lies in the excretion of DMSO. While DMSO metabolites are
primarily eliminated via the kidneys, some early excretion
occurs through the lungs.
Mild pulmonary toxicity has been well documented
and often manifests as transient and self-limited hypoxemia
during the embolization procedure. A retrospective series
of 38 Onyx embolization procedures documented transient
oxygendesaturationduring all cases, requiring supplemental
oxygen, but otherwise of no clinical consequence [12].
Anotherseriesreportedsimilartransientdesaturationduring
DMSO infusion and Onyx administration in 17 of 46
(37%) AVM embolizations [13]. One recent case report
documented noncardiogenic pulmonary edema after Onyx
embolization of an AVM [14]. The DMSO solvent was
implicated as the possible cause after other etiologies were
ruled out. The patient’s course of mechanical ventilatory
support lasted 2 days while the pulmonary edema resolved.
Our patient experienced worsening pulmonary edema
over the two-day-periembolization period. It is unclear if
one of the two embolization procedures was the oﬀender
or if there was cumulative eﬀect of the multiple Onyx
injections. The fact that the patient had a small strand
of Onyx visible in the superior sagittal sinus after the
ﬁrst embolization procedure suggests the possibility that
the pulmonary vasculature was exposed to the DMSO
solvent and even potentially Onyx microemboli, though no
radiodense material was seen grossly on the chest CT. The
patient had a persistent supplemental oxygen requirement
after the ﬁrst procedure which increased after the second
one. The echocardiogram and ECG conﬁrmed the absence
of a cardiac etiology of the pulmonary edema. Renal failure
was also ruled out as the patient’s mild increase in creatinine
did not result in oliguria or impaired solute clearance.
Negative-pressure pulmonary edema was ruled out as our
patient had no extubation diﬃculties nor was the protracted
course of the pulmonary edema consistent with a negative
pressure phenomenon. No aspirations of gastric contents
were observed during the uneventful intubations for the
procedures, nor infectious etiologies were conﬁrmed. The
ﬁnal diagnosis for the pulmonary process of ARDS was
therefore made. ARDS is a clinical diagnosis for which
there exist three sets of diagnostic criteria used by various
practitioners. The Lung Injury Score deﬁnition, American-
European Consensus Conference deﬁnition, and the Delphi
deﬁnition all have varied sensitivities and speciﬁcities for the
diagnosis [15]. Our patient met all three sets of diagnostic
criteria. The patient remained intubated for 6 more days
as his pulmonary failure improved to the point where he
tolerated operative AVM resection and was subsequently
extubated.
4.Conclusion
ARDSin this patient was likely related to Onyx embolization
giventhe lackofotherinciting factors and the closetemporal
relationship. Potential mechanisms include inﬂammatory
and toxic eﬀects of DMSO or a direct eﬀect of the ethylene
vinyl alcohol via microembolic showering. The precise
pathophysiologic mechanism as well as the true incidence of
such a complication are unknown. We encourage clinicians
to consider this uncommon but signiﬁcant complication.
Endovascular neurosurgeons should adhere to the recom-
mended volumes and injection rates of Onyx in hopes of
minimizing this potential complication. Further studies of
Onyx embolization should evaluatenoncerebral outcomesin
addition to neurologic eﬃcacy.
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